We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




新型血液分析仪给紧凑型平台带来了高标准网织红细胞分析

By LabMedica International staff writers
Posted on 25 Mar 2014
一种可靠而易于使用的新型血液分析仪自带电脑,避免了人工方法,在提高实验室生产率的同时维持标准化。

英国北安普顿Horiba公司下属的Horiba医疗用品公司推出了新型的“Pentra XLR紧凑型5分类”血液分析仪,涵盖全套的网织红细胞参数,便于研究和诊断造血和贫血。作为Pentra家族的最新成员,XLR在一套较小的平台上融汇了Horiba的金标准网织红细胞技术以及STAT功能。这使它非常适合空间有限的实验室或工作量较小的实验室,且质量不打折。

这种可靠而易于使用的新型血液分析仪自带电脑,避免了人工方法,提高了实验室生产率,保证网织红细胞计数的标准化。Pentra XLR拥有大容量自动加载器,每小时能处理80份样本,能自动重运行,具有自定义稀释率(CDR)和自动确证功能,这些都实现了无人值守的操作。用户因而能把宝贵的时间用于结果分析和更特殊的需要。

新型Pentra XLR灵活性强,其微采样系统只需53微升血液进行FBC,只需35微升血液做全网织红细胞分析,这样非常适合儿童样本或其它少量样本。网织红细胞通道利用噻唑橙技术不仅得到了高度准确的网织红细胞计数,还生成了完整的成熟度数据。它还兼容ABX Pentra ML数据管理,便于集成进现有系统。

新型Pentra XLR与Horiba公司更高通量的Pentra分析仪依托同样的网织红细胞技术,确保了结果与试剂的质量和全兼容性。这套稳定可靠的平台所有参数都有三个质控等级,在本机上就可完全追踪数据并完成确证,用户十分放心。

Horiba公司的Cleve Wright说:“Pentra XLR提高了实验室的生产率、灵活性和质量,为血液化验室创造价值。Pentra XLR拥有全面的网织红细胞分析能力,实现了高质量的详细分析,从而在紧凑的平台上做出高度准确的诊断。”

Related Links:
Horiba医疗用品公司
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
POC Immunoassay Analyzer
Procise DX
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.